Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results -- Update
Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight type 2 diabetics lose an average 15.
Novo Nordisk, drug Wegovy
Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...
Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to ...
Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...
GlobalData on MSN4d
Novo Nordisk cuts Wegovy price through new direct-to-patient online pharmacyThe Danish drugmaker has launched a new online pharmacy called NovoCare Pharmacy to cut out the middlemen it so frequently ...
The home shipments — which will be fulfilled by CenterWell Pharmacy — include Wegovy injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 ...
Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback